Ireland
--:--IST
Latest
Ireland Second in Chemical-Pharma Index, but Weaknesses Show PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda Ireland Second in Chemical-Pharma Index, but Weaknesses Show PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda
Clinical Trials in the USA / NCT06919354
Recruiting Phase 1

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

NCT06919354 · tracked via the Priya Life Science USA tracker
Sponsor
GentiBio, Inc
Phase
Phase 1
Started
2025-09-03
Last updated
2026-10-20

Condition(s) studied

Type 1 Diabetes (T1D)Type 1 Diabetes Mellitus

Investigational drug(s) / intervention(s)

GNTI-122

GNTI-122: GNTI-122 is an investigational cell therapy manufactured from a participant's own blood cells and is intended to help correct an imbalance of certain types of cells found in participants with Type 1 Diabetes.

Study summary

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety. Visit https://www.polarisstudy.com to learn more!

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: 1. Male and female participants aged ≥18 to ≤55 years with recently diagnosed (within 180 days of Screening) T1D according to American Diabetes Association criteria. 2. Participant has residual β-cell function during Screening, defined as random C-peptide ≥ 0.2 nmol/L. 3. Positive for at least one T1D-associated autoantibody. 4. Able and willing to provide written, informed consent as approved by the IRB. 5. Is confirmed positive for the HLA-DRB1\*04:01 allele. 6. Has adequate vascular access to undergo leukapheresis with no known contraindications. 8\. Female participants of childbearing potential must have a negative serum pregnancy test at Screening, must be not lactating, and must agree to protocol-specified contraception. 9\. Male participants of childbearing potential must agree to protocol specified contraception. 10\. Other than T1D, participant is in good general health. Exclusion Criteria: 1. Type 2 diabetes. 2. Experienced DKA within 4 weeks prior to or during Screening. 3. Unwilling or unable to comply with study procedures or schedule. 4. Chronic or uncontrolled medical condition. 5. Has another active or autoimmune or inflammatory disease with the exception of well-controlled Hashimoto's thyroiditis, celiac disease, or vitiligo. 6. Participation in another clinical study or active follow-up in a prior study.

Primary outcome measure(s)

  • Safety and tolerability of GNTI-122 with and without rapamycin in adult participants with recently diagnosed T1D — Week 78
    Cumulative AEs/SAEs and clinically significant abnormalities in physical exams, vital signs, clinical laboratory measures, and other clinical assessments

Trial sites (10)

FacilityCityRegionStatus
City of Hope Medical Center Duarte California Recruiting
University of California - San Diego San Diego California Recruiting
University of California - San Francisco San Francisco California Recruiting
University of Florida - Gainesville Gainesville Florida Recruiting
University of Miami, Diabetes Research Institute Miami Florida Recruiting
Joslin Diabetes Center Boston Massachusetts Recruiting
Icahn School of Medicine at Mount Sinai New York New York Recruiting
Columbia University New York New York Not Yet Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
Duke University Durham North Carolina Recruiting

More GentiBio, Inc trials in the USA

HLA Demographics Study in Adults With Type 1 Diabetes Recruiting

Other trials for the same condition

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes Recruiting
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus Active, not recruiting
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care. Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06919354 on ClinicalTrials.gov ↗ ← All trials in the USA